# EDGAR Filing Document

**Accession Number:** 0001114446
**File Stem:** 0001839882-25-032801
**Filing Date:** 2025-6
**Character Count:** 105330
**Document Hash:** 22a570b00b16bbe3bcf77dc3d7f3e1c1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001839882-25-032801.hdr.sgml**: 20250609

**ACCESSION NUMBER**: 0001839882-25-032801

**CONFORMED SUBMISSION TYPE**: 424B2

**PUBLIC DOCUMENT COUNT**: 6

**FILED AS OF DATE**: 20250609

**DATE AS OF CHANGE**: 20250609

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** UBS AG
- **CENTRAL INDEX KEY:** 0001114446
- **STANDARD INDUSTRIAL CLASSIFICATION:** NATIONAL COMMERCIAL BANKS [6021]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B2
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-283672
- **FILM NUMBER:** 251033378

**BUSINESS ADDRESS:**
- **STREET 1:** BAHNHOFSTRASSE 45
- **CITY:** ZURICH
- **STATE:** V8
- **ZIP:** CH 8001
- **BUSINESS PHONE:** 203-719-5241

**MAIL ADDRESS:**
- **STREET 1:** 600 WASHINGTON BLVD.
- **CITY:** STAMFORD
- **STATE:** CT
- **ZIP:** 06901

**The** **information in this preliminary pricing supplement is not complete and may be changed. We may not sell these securities until the pricing supplement, the accompanying product supplement and the accompanying prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these securities and we are not soliciting offers to buy these securities in any state where the offer or sale is not permitted.**

**Subject to Completion**

---

| | |
|:---|:---|
| ![](image_001.jpg)  | &nbsp;&nbsp;&nbsp; June 2025<br> Preliminary Pricing Supplement<br> Dated June 9, 2025<br> Registration Statement No. 333-283672<br> Filed pursuant to Rule 424(b)(2)<br> (To Prospectus dated February 6, 2025<br> and Product Supplement dated February 6, 2025) |

---

STRUCTURED INVESTMENTS

Opportunities in U.S. Equities

Trigger Jump Securities due on or about December 24, 2026

**$● Based on the Performance of the common stock of Eli Lilly and Company**

**Principal at Risk Securities**

The Trigger Jump Securities (the "securities") are unsubordinated, unsecured debt obligations issued by UBS AG ("UBS" or the "issuer") based on the performance of common stock of Eli Lilly and Company (the "underlying equity"). The payment at maturity, if any, will depend on the percentage and direction change in the closing price of the underlying equity from the trade date (its "initial price") to the valuation date (its "final price", and such percentage change, the "underlying return"). The securities are for investors who are willing to risk their principal and forgo current income in exchange for the potential to receive a return equal to the digital return if the underlying return is zero or positive. At maturity, if the underlying return is zero or positive, investors will receive the stated principal amount of their investment plus a return equal to the digital return of 32.00%. If the underlying return is negative and the final price is equal to or greater than the trigger price, investors will receive their stated principal amount of their investment. If, however, the underlying return is negative and the final price is less than the trigger price, the investor is fully exposed to a loss of their initial investment that is equal to the underlying return. **Accordingly, the securities do not guarantee any return of principal at maturity and you could lose a significant portion or all of your initial investment. The securities are unsubordinated, unsecured debt obligations issued by UBS, and all payments on the securities are subject to the credit risk of UBS. If UBS were to default on its obligations you may not receive any amounts owed to you under the securities and you could lose your entire initial investment.**

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; SUMMARY TERMS | &nbsp;&nbsp;&nbsp; SUMMARY TERMS | &nbsp;&nbsp;&nbsp; SUMMARY TERMS |
| &nbsp;&nbsp; **Issuer:** | &nbsp;&nbsp; **Issuer:** | &nbsp;&nbsp;&nbsp;&nbsp; UBS AG London Branch  |
| &nbsp;&nbsp; **Underlying equity:** | &nbsp;&nbsp; **Underlying equity:** | &nbsp;&nbsp;&nbsp;&nbsp; The Common stock of Eli Lilly and Company (Bloomberg Ticker: "LLY UN") |
| &nbsp;&nbsp; **Aggregate principal amount:** | &nbsp;&nbsp; **Aggregate principal amount:** | &nbsp;&nbsp;&nbsp;&nbsp; $●  |
| &nbsp;&nbsp; **Stated principal amount:** | &nbsp;&nbsp; **Stated principal amount:** | &nbsp;&nbsp;&nbsp;&nbsp; $1,000 per security |
| &nbsp;&nbsp; **Issue price:** | &nbsp;&nbsp; **Issue price:** | &nbsp;&nbsp;&nbsp;&nbsp; $1,000 per security (see "Commissions and issue price" below) |
| &nbsp;&nbsp; **Denominations:** | &nbsp;&nbsp; **Denominations:** | &nbsp;&nbsp;&nbsp;&nbsp; $1,000 per security and integral multiples thereof |
| &nbsp;&nbsp; **Interest:** | &nbsp;&nbsp; **Interest:** |  |
| &nbsp;&nbsp; **Pricing date:** | &nbsp;&nbsp; **Pricing date:** | &nbsp;&nbsp;&nbsp;&nbsp; Expected to be June 20, 2025, subject to postponement in the event of a market disruption event, as described in the accompanying product supplement. In the event that we make any change to the expected pricing date and original issue date, the calculation agent may adjust the valuation date and the maturity date to ensure that the stated term of the securities remains the same. |
| &nbsp;&nbsp; **Original issue date:** | &nbsp;&nbsp; **Original issue date:** | &nbsp;&nbsp;&nbsp;&nbsp; Expected to be June 25, 2025 (3 business days after the pricing date), subject to postponement in the event of a market disruption event, as described in the accompanying product supplement. Under Rule 15c6-1 of the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day (T+1), unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade the securities in the secondary market on any date prior to one business day before delivery of the securities will be required, by virtue of the fact that each security initially will settle in three business days (T+3), to specify alternative settlement arrangements to prevent a failed settlement of the secondary market trade. |
| &nbsp;&nbsp; **Valuation date:** | &nbsp;&nbsp; **Valuation date:** | &nbsp;&nbsp;&nbsp;&nbsp; Expected to be December 21, 2026 (to be determined on the pricing date and expected to be approximately 18 months after the pricing date), subject to postponement in the event of a market disruption event, as described in the accompanying product supplement |
| &nbsp;&nbsp; **Maturity date:** | &nbsp;&nbsp; **Maturity date:** | &nbsp;&nbsp;&nbsp;&nbsp; Expected to be December 24, 2026 (to be determined on the pricing date and expected to be 3 business days after the valuation date), subject to postponement for certain market disruption events and as described under "General Terms of the Securities — Market Disruption Events" and "— Payment Dates — Maturity Date" in the accompanying product supplement. |
| &nbsp;&nbsp; **Payment at maturity:** | &nbsp;&nbsp; **Payment at maturity:** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ￭ If the underlying return is **zero or positive**:<br>*$1,000 + ($1,000 × the Digital Return)*<br> ￭ If the underlying return is **negative** and the final price is **equal to or greater than** the trigger price:<br> *Stated Principal Amount of $1,000*<br> ￭ If underlying return is **negative** and the final price is **less than** the trigger price:<br> *$1,000 + ($1,000 × Underlying Return)*<br> **Under these circumstances, you will lose a percentage of your stated principal amount equal to the underlying return and, in extreme situations, you could lose all of your initial investment.** |
| &nbsp;&nbsp; **Underlying return:** | &nbsp;&nbsp; **Underlying return:** | &nbsp;&nbsp;&nbsp;&nbsp; The quotient, expressed as a percentage, of the following formula:<br> <u>Final</u> <u>Price</u> <u>– Initial</u> <u>Price</u><br>Initial Price |
| &nbsp;&nbsp; **Digital return:** | &nbsp;&nbsp; **Digital return:** | &nbsp;&nbsp;&nbsp;&nbsp; 32.00% |
| &nbsp;&nbsp; **Initial price:** | &nbsp;&nbsp; **Initial price:** | &nbsp;&nbsp;&nbsp;&nbsp; $●, which is equal to the closing price of the underlying equity on the pricing date (as may be adjusted in the case of certain adjustment events as described under "General Terms of the Securities — Antidilution Adjustments for Securities Linked to an Underlying Equity or Equity Basket Asset", "— Reorganization Events for Securities Linked to an Underlying Equity or Equity Basket Asset" and "— Delisting of, Suspension of Trading in, or Change in Law Affecting, an Underlying Equity" in the accompanying product supplement). |
| &nbsp;&nbsp; **Trigger price:** | &nbsp;&nbsp; **Trigger price:** | &nbsp;&nbsp;&nbsp;&nbsp; $●, which is equal to 80.00% of the initial price (as may be adjusted in the case of certain adjustment events as described under "General Terms of the Securities — Antidilution Adjustments for Securities Linked to an Underlying Equity or Equity Basket Asset", "— Reorganization Events for Securities Linked to an Underlying Equity or Equity Basket Asset" and "— Delisting of, Suspension of Trading in, or Change in Law Affecting, an Underlying Equity" in the accompanying product supplement). |
| &nbsp;&nbsp; **Final price:** | &nbsp;&nbsp; **Final price:** | &nbsp;&nbsp;&nbsp;&nbsp; The closing price of the underlying equity on the valuation date, as determined by the calculation agent |
| &nbsp;&nbsp; **CUSIP / ISIN:** | &nbsp;&nbsp; **CUSIP / ISIN:** | &nbsp;&nbsp;&nbsp;&nbsp; 90308VW31 / US90308VW313 |
| &nbsp;&nbsp; **Listing:** | &nbsp;&nbsp; **Listing:** | &nbsp;&nbsp;&nbsp;&nbsp; The securities will not be listed or displayed on any securities exchange or any electronic communications network. |
| &nbsp;&nbsp; **Agent:** | &nbsp;&nbsp; **Agent:** | &nbsp;&nbsp;&nbsp;&nbsp; UBS Securities LLC |
| &nbsp;&nbsp; **Commissions and issue price:** | &nbsp;&nbsp; **Price to Public**<sup>(1)</sup> | &nbsp;&nbsp; **Proceeds to Issuer** |
| &nbsp;&nbsp; **Per security:** | &nbsp;&nbsp;&nbsp;&nbsp; 100% | &nbsp;&nbsp;&nbsp;&nbsp; 97.50% |
| &nbsp;&nbsp;&nbsp; **Total** **:** | &nbsp;&nbsp;&nbsp;&nbsp; $●  | &nbsp;&nbsp;&nbsp;&nbsp; $●  |

---

&nbsp;&nbsp;&nbsp;&nbsp;*(1)* *UBS Securities LLC will purchase from UBS AG the securities at the price to public less a fee of $25.00 per $1,000.00 stated principal amount of securities. UBS Securities LLC will agree to resell all of the securities to Morgan Stanley Smith Barney LLC ("Morgan Stanley Wealth Management") at an underwriting discount which reflects:* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(a)* *a fixed sales commission of $20.00 per $1,000.00 stated principal amount of securities that Morgan Stanley Wealth Management sells and* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(b)* *a fixed structuring fee of $5.00 per $1,000.00 stated principal amount of securities that Morgan Stanley Wealth Management sells, each payable to Morgan Stanley Wealth Management. See "Supplemental plan of distribution (conflicts of interest); secondary markets (if any)".* 

The estimated initial value of the securities as of the pricing date is expected to be between $939.60 and $969.60. The range of the estimated initial value of the securities was determined on the date of this document by reference to UBS' internal pricing models, inclusive of the internal funding rate. For more information about secondary market offers and the estimated initial value of the securities, see "Risk Factors — Estimated Value Considerations" and "— Limited Or No Secondary Market And Secondary Market Price Considerations" on page 10 of this document.

**Notice to investors: the securities are significantly riskier than conventional debt instruments. The issuer is not necessarily obligated to repay the full stated principal amount of the securities at maturity, and the securities can have downside market risk similar to the underlying equity. This market risk is in addition to the credit risk inherent in purchasing a debt obligation of UBS. You should not purchase the securities if you do not understand or are not comfortable with the significant risks involved in investing in the securities.**

**You should carefully consider the risks described under "Risk Factors" beginning on page 9 and under "Risk Factors" beginning on page PS-9 of the product supplement before purchasing any securities. Events relating to any of those risks, or other risks and uncertainties, could adversely affect the market value of, and the return on, your securities. You may lose a significant portion or all of your initial investment in the securities.**

**Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this document, the accompanying product supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.**

The securities are not bank deposits and are not insured by the Federal Deposit Insurance Corporation or any other governmental agency.

---

| | |
|:---|:---|
| [<u>Product supplement dated February 6, 2025</u>](http://www.sec.gov/Archives/edgar/data/1114446/000183988225007685/ubs_424b2-03670.htm) | [<u>Prospectus dated February 6, 2025</u>](http://www.sec.gov/Archives/edgar/data/1114446/000119312525021845/d936490d424b3.htm) |

---

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

Additional Information About UBS and the Securities

UBS AG ("UBS") has filed a registration statement (including a prospectus as supplemented by a product supplement) with the Securities and Exchange Commission (the "SEC") for the securities to which this document relates. You should read these documents and any other documents relating to this offering that UBS has filed with the SEC for more complete information about UBS and this offering. You may obtain these documents for free from the SEC website at www.sec.gov. Our Central Index Key, or CIK, on the SEC web site is 0001114446.

**You may access these documents on the SEC website at www.sec.gov as follows:**

---

| | |
|:---|:---|
| &nbsp;&nbsp; ￭  | &nbsp;&nbsp; Prospectus dated February 6, 2025:<br><u>http://www.sec.gov/Archives/edgar/data/1114446/000119312525021845/d936490d424b3.htm</u> |
| &nbsp;&nbsp; ￭  | &nbsp;&nbsp; Product supplement dated February 6, 2025:<br>[<u>http://www.sec.gov/Archives/edgar/data/1114446/000183988225007685/ubs_424b2-03670.htm</u>](http://www.sec.gov/Archives/edgar/data/1114446/000183988225007685/ubs_424b2-03670.htm) |

---

*References to "UBS," "we," "our" and "us" refer only to UBS AG and not to its consolidated subsidiaries. In this document, the "securities" refers to the Trigger Jump that are offered hereby. Also, references to the "accompanying prospectus" mean the UBS prospectus titled "Debt Securities and Warrants," dated February 6, 2025, and references to the "accompanying product supplement" mean the UBS product supplement titled "Market-Linked Securities Product Supplement", dated February 6, 2025.*

You should rely only on the information incorporated by reference or provided in this document, the accompanying product supplement or the accompanying prospectus. We have not authorized anyone to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this document, the accompanying product supplement or the accompanying prospectus is accurate as of any date other than the date on the front of the document.

UBS reserves the right to change the terms of, or reject any offer to purchase, the securities prior to their issuance. In the event of any changes to the terms of the securities, UBS will notify you and you will be asked to accept such changes in connection with your purchase. You may also choose to reject such changes in which case UBS may reject your offer to purchase.

In the event of any discrepancies between this document, the accompanying product supplement and the accompanying prospectus, the following hierarchy will govern: first, this document; second, the accompanying product supplement; and finally, the accompanying prospectus.

June 2025 Page 2

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

Investment Overview

Trigger Jump Securities

The Trigger Jump Securities Based on the Performance of common stock of Eli Lilly and Company due on or about December 24, 2026 can be used:

￭As an alternative to direct exposure to the underlying equity that provides a potential return equal to the digital return if the underlying equity remains flat or appreciates over the term of the securities; however, by investing in the securities, you will not be entitled to participate in any appreciation of the underlying equity or to receive any dividends paid with respect to the underlying equity and you will not receive any interest payments. You should carefully consider whether an investment that features a capped return and that does not provide for any dividends or interest payments is appropriate for you.

￭To provide a fixed return and potentially outperform the underlying equity in a moderately bullish scenario.

￭To provide a return of principal in the event that the underlying return is negative and the final price is equal to or greater than the trigger price.

If the final price is less than the trigger price, the securities are exposed on a 1:1 basis to the negative performance of the underlying equity.

---

| | |
|:---|:---|
| &nbsp;&nbsp; **Maturity:** | &nbsp;&nbsp;&nbsp; Approximately 18 months |
| &nbsp;&nbsp; **Digital return:** | &nbsp;&nbsp;&nbsp; 32.00% |
| &nbsp;&nbsp; **Trigger price:** | &nbsp;&nbsp;&nbsp; 80.00% of the initial price |
| &nbsp;&nbsp; **Interest:** |  |
| &nbsp;&nbsp; **Minimum payment at maturity:** | &nbsp;&nbsp;&nbsp; None. Investors may lose all of their initial investment in the securities. |
| &nbsp;&nbsp; **Listing:** | &nbsp;&nbsp;&nbsp; The securities will not be listed or displayed on any securities exchange or any electronic communications network. |

---

Key Investment Rationale

Investors can use the securities to realize a return equal to 32.00% if the underlying equity remains flat or appreciates from the initial price to the final price and obtain contingent protection against a loss of principal in the event that the underlying return is negative and the final price is equal to or greater than the trigger price. If, however, the final price is less than the trigger price, the investor is fully exposed to a loss of their initial investment that is equal to the underlying return. Investors may lose all of their initial investment in the securities.

Investors will not be entitled to receive any dividends paid with respect to the underlying equity and the securities do not pay periodic interest. You should carefully consider whether an investment that does not provide for any dividends or periodic interest is appropriate for you. **The payment scenarios below do not show any effect of lost dividend yield over the term of the securities.**

---

| | |
|:---|:---|
| &nbsp;&nbsp; **Upside Scenario**  | &nbsp;&nbsp;&nbsp;&nbsp; If the underlying return is zero or positive, at maturity you will receive the stated principal amount of $1,000 plus a return equal to the digital return. In no event will your return on the securities exceed the digital return, regardless of the appreciation of the underlying equity. |
| &nbsp;&nbsp; **Par Scenario** | &nbsp;&nbsp;&nbsp;&nbsp; If the underlying return is negative and the final price is equal to or greater than the trigger price, at maturity you will receive the stated principal amount. |
| &nbsp;&nbsp; **Downside Scenario**  | &nbsp;&nbsp;&nbsp;&nbsp; If the underlying return is negative and the final price is less than the trigger price, at maturity you will receive less than 80.00% of the stated principal amount, if anything, resulting in a percentage loss of your initial investment equal to the underlying return. For example, if the underlying return is -40%, each security will redeem for $600.00, or 60% of the stated principal amount. **There is no minimum payment on the securities and you could lose all of your initial investment.**  |

---

June 2025 Page 3

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

Investor Suitability

**The securities may be suitable for you if:** 

■You fully understand and are willing to accept the risks of an investment in the securities, including the risk of loss of all of your initial investment.

■You can tolerate a loss of a significant portion or all of your initial investment and are willing to make an investment that may have the same downside market risk as an investment in the underlying equity.

■You believe the final price of the underlying equity will be equal to or greater than the initial price and you can tolerate receiving a payment at maturity that will be significantly less than the stated principal amount and may be zero if the final price is less than the trigger price.

■You believe the price of the underlying equity will remain flat or appreciate over the term of the securities.

■You can tolerate fluctuations in the price of the securities prior to maturity that may be similar to or exceed the downside fluctuations in the price of the underlying equity.

■You understand and accept that your potential return on the securities is limited to the digital return and you would be willing to invest in the securities based on the digital return indicated on the cover hereof.

■You do not seek current income from your investment and are willing to forgo any dividends paid on the underlying equity.

■You are willing and able to hold the securities to maturity, a term of approximately 18 months, and accept that there may be little or no secondary market for the securities.

■You understand and are willing to accept the single equity risk associated with the securities and the risks associated with the underlying equity.

■You are willing to assume the credit risk of UBS for all payments under the securities, and understand that if UBS defaults on its obligations you may not receive any amounts due to you, including any repayment of principal.

■You understand that the estimated initial value of the securities determined by our internal pricing models is lower than the issue price and that should UBS Securities LLC or any affiliate make secondary markets for the securities, the price (not including their customary bid-ask spreads) will temporarily exceed the internal pricing model price.

**The securities may not be suitable for you if:** 

■You do not fully understand or are not willing to accept the risks inherent in an investment in the securities, including the risk of loss of all of your initial investment.

■You require an investment designed to provide a full return of principal at maturity.

■You cannot tolerate a loss of a significant portion or all of your initial investment, or you are not willing to make an investment that may have the same downside market risk as an investment in the underlying equity.

■You believe that the price of the underlying equity will decline during the term of the securities or you believe that the underlying return will be positive and that such appreciation is likely to exceed the digital return indicated on the cover hereof.

■You seek an investment that has an unlimited return potential or you would be unwilling to invest in the securities based on the digital return indicated on the cover hereof.

■You cannot tolerate fluctuations in the price of the securities prior to maturity that may be similar to or exceed the downside fluctuations in the price of the underlying equity.

■You seek current income from your investment or prefer to receive the dividends paid on the underlying equity.

■You are unable or unwilling to hold the securities to maturity, a term of approximately 18 months, or seek an investment for which there will be an active secondary market.

■You do not understand or are unwilling to accept the single equity risk associated with the securities and the risks associated with the underlying equity.

■You are not willing to assume the credit risk of UBS for all payments under the securities, including any repayment of principal.

June 2025 Page 4

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

How the Securities Work

Hypothetical Examples

The below examples are based on the following terms and are purely hypothetical (the actual terms of your securities will be determined on the pricing date and will be specified in the final pricing supplement):

Investors will not be entitled to receive any dividends paid with respect to the underlying equity. You should carefully consider whether an investment that does not provide for any dividends or periodic interest is appropriate for you. **The payment scenarios below do not show any effect of lost dividend yield over the term of the securities.**

The below examples are based on the following terms:

---

| | |
|:---|:---|
| &nbsp;&nbsp; **Stated principal amount:** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $1,000 per security |
| &nbsp;&nbsp; **Digital return:** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32.00% |
| &nbsp;&nbsp; **Hypothetical initial price:** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $100.00 |
| &nbsp;&nbsp; **Hypothetical trigger price:** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $80.00, which is 80.00% of the hypothetical initial price |
| &nbsp;&nbsp; **Minimum payment at maturity:** |  |

---

**EXAMPLE 1: The underlying equity appreciates over the term of the securities by a percentage greater than the digital return, and investors receive the stated principal amount plus a return equal to the digital return at maturity.** 

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; Final Price | &nbsp;&nbsp; Final Price | &nbsp;&nbsp; $160.00 |
| &nbsp;&nbsp; Underlying Return | &nbsp;&nbsp; ($160.00 - $100.00) / $100.00 = 60.00% | &nbsp;&nbsp; ($160.00 - $100.00) / $100.00 = 60.00% |
| &nbsp;&nbsp; Payment at Maturity | &nbsp;&nbsp; = $1,000 + ($1,000 × the Digital Return) | &nbsp;&nbsp; = $1,000 + ($1,000 × the Digital Return) |
|  | &nbsp;&nbsp; = $1,000 + ($1,000 × 32.00%) | &nbsp;&nbsp; = $1,000 + ($1,000 × 32.00%) |
|  | &nbsp;&nbsp; = $1,320.00 (Payment at Maturity) | &nbsp;&nbsp; = $1,320.00 (Payment at Maturity) |

---

In **Example 1**, the final price is equal to or greater than the initial price and the underlying return is 60.00%. Therefore, at maturity, investors receive the stated principal amount plus a return equal to the digital return, resulting in a payment at maturity of $1,320.00 per security (a total return of 32.00%).

**EXAMPLE 2: The underlying equity remains flat over the term of the securities, and investors receive the stated principal amount plus a return equal to the digital return at maturity.** 

---

| | |
|:---|:---|
| &nbsp;&nbsp; Final Price | &nbsp;&nbsp; $100.00 |
| &nbsp;&nbsp; Underlying Return | &nbsp;&nbsp; ($100.00 - $100.00) / $100.00 = 0.00% |
| &nbsp;&nbsp; Payment at Maturity | &nbsp;&nbsp; = $1,000 + ($1,000 × the Digital Return) |
|  | &nbsp;&nbsp; = $1,000 + ($1,000 × 32.00%) |
|  | &nbsp;&nbsp; = $1,320.00 (Payment at Maturity) |

---

In **Example 2**, the final price is equal to or greater than the initial price. Therefore, at maturity, investors receive the stated principal amount plus a return equal to the digital return, resulting in a payment at maturity of $1,320.00 per security (a total return of 32.00%).

June 2025 Page 5

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

**EXAMPLE 3: The underlying equity declines over the term of the securities but the final price is equal to or greater than the trigger price and investors receive the stated principal amount at maturity.** 

---

| | |
|:---|:---|
| &nbsp;&nbsp; Final Price | &nbsp;&nbsp; $95.00 |
| &nbsp;&nbsp; Underlying Return | &nbsp;&nbsp; ($95.00 - $100.00) / $100.00 = -5.00% |
| &nbsp;&nbsp; Payment at Maturity | &nbsp;&nbsp; = $1,000.00 (Payment at Maturity) |

---

In **Example 3**, the underlying return is negative but the final price is equal to or greater than the trigger price. Therefore, at maturity, investors receive the stated principal amount of $1,000.00 per security (a total return of 0.00%), even though the underlying return is negative.

**EXAMPLE 4: The underlying equity declines over the term of the securities and the final price is less than the trigger price and investors receive less than the stated principal amount at maturity.** 

---

| | |
|:---|:---|
| &nbsp;&nbsp; Final Price | &nbsp;&nbsp; $50.00 |
| &nbsp;&nbsp; Underlying Return | &nbsp;&nbsp; ($50.00 - $100.00) / $100.00 = -50.00% |
| &nbsp;&nbsp; Payment at Maturity | &nbsp;&nbsp; =$1,000 + ($1,000 × Underlying Return) |
|  | &nbsp;&nbsp; =$1,000 + ($1,000 × -50.00%) |
|  | &nbsp;&nbsp; = $1,000 + (-$500.00) |
|  | &nbsp;&nbsp; =$500.00 (Payment at Maturity) |

---

In **Example 4**, the underlying return is negative and final price is less than the trigger price. Therefore, at maturity, investors are fully exposed to the decline in the price of the underlying equity from its initial price, resulting in a payment at maturity of $500.00 per security (a loss of 50.00%).

June 2025 Page 6

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

**How it works**

￭**Upside Scenario.** If the underlying return is zero or positive, investors will receive the stated principal amount of $1,000 plus a return equal to the digital return of 32.00%.

￭If the underlying return is 0.00%, investors will receive a 32.00% return, or $1,320.00 per security.

￭If the underlying return is 20.00%, investors will receive a 32.00% return, or $1,320.00 per security.

￭If the underlying return is 60.00%, investors will receive a 32.00% return, or $1,320.00 per security.

￭**Par Scenario.** If the underlying return is negative but the final price is equal to or greater than the trigger price, investors will receive an amount equal to the $1,000 stated principal amount.

￭If the underlying return is -5.00%, investors will receive an amount equal to the $1,000 stated principal amount.

￭**Downside Scenario.** If the underlying return is negative and the final price is less than the trigger price, investors will receive an amount that is less than 80.00% of the $1,000 stated principal amount, if anything, resulting in a percentage loss of their initial investment that is equal to the underlying return.

￭If the underlying return is -40.00%, investors would lose 40.00% of the stated principal amount and receive only $600.00 per security at maturity, or 60.00% of the stated principal amount. **There is no minimum payment at maturity on the securities and investors may lose all of their initial investment.**

June 2025 Page 7

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

Payment at Maturity

At maturity, investors will receive for each $1,000 stated principal amount of securities that they hold an amount in cash based upon the underlying return of the underlying equity on the valuation date, as determined as follows:

***If the underlying return is zero or positive:***

**$1,000 + ($1,000 × the digital return)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp; **Stated Principal Amount** |  | &nbsp;&nbsp; **Stated Principal Amount** | &nbsp;&nbsp; **Digital Return** | &nbsp;&nbsp; **Digital Return** |
| &nbsp;&nbsp; $1000  | &nbsp;&nbsp; + | &nbsp;&nbsp; $1000 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; × | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32.00%  |

---

***If the underlying return is negative and the final price is equal to or greater than the trigger price:***

**the Stated Principal Amount of $1,000**

---

| |
|:---|
| &nbsp;&nbsp; **Stated Principal Amount** |
| &nbsp;&nbsp; $1000 |

---

***If the underlying return is negative and the final price is less than the trigger price:***

**$1,000 + ($1,000 × Underlying Return)**

![](image_002.jpg)

**Accordingly, if the final price is less than the trigger price, you will lose a percentage of your principal amount equal to the underlying return and, in extreme situations, you could lose all of your initial investment.**

June 2025 Page 8

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

Risk Factors

*The following is a non-exhaustive list of certain key risk factors for investors in the securities. For further discussion of these and other risks, you should read the section entitled "Risk Factors" in the accompanying product supplement and "Considerations Relating to Indexed Securities" in the accompanying prospectus. We also urge you to consult your investment, legal, tax, accounting and other advisors concerning an investment in the securities.*

***Risks Relating to Return Characteristics***

￭**The securities do not pay interest or guarantee return of the stated principal amount and your investment in the securities may result in a loss.** The terms of the securities differ from those of ordinary debt securities in that the securities do not pay interest or guarantee the return of any of the stated principal amount at maturity. If the underlying return is negative and the final price is less than the trigger price, you will lose a percentage of your principal amount equal to the underlying return and, in extreme situations, you could lose all of your initial investment. **There is no minimum payment at maturity on the securities and, accordingly, you could lose a significant portion and, in extreme situations, all of your initial investment.**

￭**Your potential return on the securities is limited to the digital return.** The return potential of the securities is limited to the digital return indicated on the cover hereof. Therefore, you will not benefit from any positive underlying return that exceeds the digital return and your return on the securities may be less than it would be in an investment in the underlying equity.

￭**The digital return applies only if you hold the securities to maturity.** You should be willing to hold the securities to maturity. If you are able to sell the securities prior to maturity in the secondary market, the price you receive will likely not reflect the full economic value of the securities and the return you realize may be less than the digital return, even if the then-current price of the underlying equity is equal to or greater than the initial price. You can receive the full benefit of the digital return from UBS only if you hold the securities to maturity.

■**The contingent repayment of principal at maturity applies only at maturity.** You should be willing to hold the securities to maturity. If you are able to sell the securities prior to maturity in the secondary market, you may have to sell them at a loss relative to your initial investment even if the then-current price of the underlying equity is equal to or greater than the initial price.

￭**Owning the securities is not the same as owning the underlying equity**. The return on the securities may not reflect the return you would realize if you actually owned the underlying equity. For example, your return on the securities is limited to the digital return, while the potential return on a direct investment in the underlying equity would be unlimited. Furthermore, you will not receive or be entitled to receive any dividend payments or other distributions during the term of the securities, and any such dividends or distributions will not be factored into the calculation of the payment at maturity on the securities. In addition, as an owner of the securities, you will not have voting rights or any other rights that a holder of the underlying equity would have.

***Risks Relating to Characteristics of the Underlying Equity***

■**Single equity risk.** The closing price of the underlying equity can rise or fall sharply due to factors specific to that underlying equity and the issuer of such underlying equity (the "underlying equity issuer"), such as stock price volatility, earnings, financial conditions, corporate, industry and regulatory developments, management changes and decisions and other events, as well as general market factors, such as general stock market volatility and levels, interest rates and economic and political conditions. You, as an investor in the securities, should make your own investigation into the underlying equity issuer and the underlying equity for your securities. For additional information regarding the underlying equity, please see "Information About the Underlying Equity" below and the underlying equity issuer's SEC filings referred to in this section. **We urge you to review financial and other information filed periodically by the underlying equity issuer with the SEC.**

￭**There can be no assurance that the investment view implicit in the securities will be successful.** It is impossible to predict whether and the extent to which the price of the underlying equity will rise or fall and there can be no assurance that the underlying return will be zero or positive. The final price (and therefore the underlying return) will be influenced by complex and interrelated political, economic, financial and other factors that affect the underlying equity. You should be willing to accept the downside risks of owning equities in general and the underlying equity in particular, and the risk of losing a significant portion or all of your initial investment.

■**No affiliation with the underlying equity issuer.** The underlying equity issuer is not an affiliate of ours, is not involved with the offering in any way, and has no obligation to consider your interests in taking any corporate actions that might affect the value of the securities. We have not made any due diligence inquiry with respect to the underlying equity in connection with the offering.

June 2025 Page 9

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

***Estimated Value Considerations***

￭**The issue price you pay for the securities will exceed their estimated initial value.** The issue price you pay for the securities will exceed their estimated initial value as of the pricing date due to the inclusion in the issue price of the underwriting discount, hedging costs, issuance and other costs and projected profits. As of the close of the relevant markets on the pricing date, we will determine the estimated initial value of the securities by reference to our internal pricing models and the estimated initial value of the securities will be set forth in the final pricing supplement. The pricing models used to determine the estimated initial value of the securities incorporate certain variables, including the price, volatility and any dividends paid on the underlying equity, prevailing interest rates, the term of the securities and our internal funding rate. Our internal funding rate is typically lower than the rate we would pay to issue conventional fixed or floating rate debt securities of a similar term. The underwriting discount, hedging costs, issuance and other costs, projected profits and the difference in rates will reduce the economic value of the securities to you. Due to these factors, the estimated initial value of the securities as of the pricing date will be less than the issue price you pay for the securities.

￭**The estimated initial value is a theoretical price and the actual price that you may be able to sell your securities in any secondary market (if any) at any time after the pricing date may differ from the estimated initial value.** The value of your securities at any time will vary based on many factors, including the factors described above and in "Risks Relating to Characteristics of the Underlying Equity — Single equity risk" above and is impossible to predict. Furthermore, the pricing models that we use are proprietary and rely in part on certain assumptions about future events, which may prove to be incorrect. As a result, after the pricing date, if you attempt to sell the securities in the secondary market, the actual value you would receive may differ, perhaps materially, from the estimated initial value of the securities determined by reference to our internal pricing models. The estimated initial value of the securities does not represent a minimum or maximum price at which we or any of our affiliates would be willing to purchase your securities in any secondary market at any time.

￭**Our** **actual profits may be greater or less than the differential between the estimated initial value and the issue price of the securities as of the pricing date**. We may determine the economic terms of the securities, as well as hedge our obligations, at least in part, prior to the pricing date. In addition, there may be ongoing costs to us to maintain and/or adjust any hedges and such hedges are often imperfect. Therefore, our actual profits (or potentially, losses) in issuing the securities cannot be determined as of the pricing date and any such differential between the estimated initial value and the issue price of the securities as of the pricing date does not reflect our actual profits. Ultimately, our actual profits will be known only at the maturity of the securities.

***Risks Relating to Liquidity and Secondary Market Price Considerations***

￭**There may be little or no secondary market for the securities.** The securities will not be listed or displayed on any securities exchange or any electronic communications network. UBS Securities LLC and its affiliates intend, but are not required to make a market for the securities and may stop making a market at any time. If you are able to sell your securities prior to maturity, you may have to sell them at a substantial loss. Furthermore, there can be no assurance that a secondary market for the securities will develop. The estimated initial value of the securities does not represent a minimum or maximum price at which we or any of our affiliates would be willing to purchase your securities in any secondary market at any time.

■**The price at which UBS Securities LLC and its affiliates may offer to buy the securities in the secondary market (if any) may be greater than UBS' valuation of the securities at that time, greater than any other secondary market prices provided by unaffiliated dealers (if any) and, depending on your broker, greater than the valuation provided on your customer account statements.** For a limited period of time following the issuance of the securities, UBS Securities LLC or its affiliates may offer to buy or sell such securities at a price that exceeds (i) our valuation of the securities at that time based on our internal pricing models, (ii) any secondary market prices provided by unaffiliated dealers (if any) and (iii) depending on your broker, the valuation provided on customer account statements. The price that UBS Securities LLC may initially offer to buy such securities following issuance will exceed the valuations indicated by our internal pricing models due to the inclusion for a limited period of time of the aggregate value of the underwriting discount, hedging costs, issuance costs and theoretical projected trading profit. The portion of such amounts included in our price will decline to zero on a straight line basis over a period ending no later than the date specified under "Supplemental plan of distribution (conflicts of interest); secondary markets (if any)." Thereafter, if UBS Securities LLC or an affiliate makes secondary markets in the securities, it will do so at prices that reflect our estimated value determined by reference to our internal pricing models at that time. The temporary positive differential relative to our internal pricing models arises from requests from and arrangements made by UBS Securities LLC with the selling agents of structured debt securities such as the securities. As described above, UBS Securities LLC and its affiliates are not required to make a market for the securities and may stop making a market at any time. The price at which UBS Securities LLC or an affiliate may make secondary markets at any time (if at all) will also reflect its then current bid-ask spread for similar sized trades of structured debt securities. UBS Securities LLC reflects this temporary positive differential on its customer statements. Investors should inquire as to the valuation provided on customer account statements provided by unaffiliated dealers.

￭**Price of the securities prior to maturity**. The market price of the securities will be influenced by many unpredictable and interrelated factors, including the price of the underlying equity; the volatility of the underlying equity; the dividend rate paid on the underlying equity; the time remaining to the maturity of the securities; interest rates in the markets; geopolitical

June 2025 Page 10

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

conditions and economic, financial, political, force majeure and regulatory or judicial events; the creditworthiness of UBS and the then current bid-ask spread for the securities.

￭**Impact** **of fees and the use of internal funding rates rather than secondary market credit spreads on secondary market prices.** All other things being equal, the use of the internal funding rates described above under "— Estimated Value Considerations" as well as the inclusion in the issue price of the underwriting discount, hedging costs, issuance and other costs and any projected profits are, subject to the temporary mitigating effect of UBS Securities LLC's and its affiliates' market making premium, expected to reduce the price at which you may be able to sell the securities in any secondary market.

***Risks Relating to Hedging Activities and Conflicts of Interest***

￭**Potential conflicts of interest.** We and our affiliates may engage in business related to the underlying equity, which may present a conflict between our obligations as issuer and you, as a holder of the securities. There are also potential conflicts of interest between you and the calculation agent, which will be an affiliate of UBS. The calculation agent will determine the initial price and the final price and whether the final price of the underlying equity is less than the trigger price. Determinations made by the calculation agent, including with respect to the occurrence or non-occurrence of market disruption events, may affect the payout to you at maturity. As UBS determines the economic terms of the securities, including the digital return and trigger price, and such terms include the underwriting discount, hedging costs, issuance and other costs and projected profits, the securities represent a package of economic terms. There are other potential conflicts of interest insofar as an investor could potentially get better economic terms if that investor entered into exchange-traded and/or OTC derivatives or other instruments with third parties, assuming that such instruments were available and the investor had the ability to assemble and enter into such instruments. Furthermore, given that UBS Securities LLC and its affiliates temporarily maintain a market making premium, it may have the effect of discouraging UBS Securities LLC and its affiliates from recommending sale of your securities in the secondary market.

In addition, we or one of our affiliates may enter into swap agreements or related hedging activities with the dealer or its affiliates in connection with the securities, which could cause the economic interests of UBS, the dealer or our or their respective affiliates to be adverse to your interests as an investor in the securities. If the dealer or any of its affiliates conduct hedging activities for us or our affiliate in connection with the securities and earns profits in connection with such hedging activities, such profit will be in addition to the underwriting compensation it receives for the sale of the securities to you. You should be aware that the potential to receive compensation both for hedging activities and sales may create a further incentive for the dealer to sell the securities to you.

￭**Hedging and trading activities by the calculation agent and its affiliates could potentially affect the value of, and any amounts payable on, the securities.** The hedging or trading activities of the issuer's affiliates and of any other hedging counterparty with respect to the securities on or prior to the pricing date and prior to maturity could adversely affect the value of, and any amounts payable on, the securities. These hedging or trading activities on or prior to the pricing date could potentially affect the initial price and, as a result, the trigger price. Additionally, these hedging or trading activities during the term of the securities could potentially affect the price of the underlying equity on the determination dates and, accordingly, whether the securities are redeemed early and, if the securities are not called prior to maturity, the payout to you at maturity. It is possible that these hedging or trading activities could result in substantial returns for us or our affiliates while the value of the securities declines.

￭**We may engage in business with or involving the underlying equity issuer without regard to your interests.** We or our affiliates may presently or from time to time engage in business with the underlying equity issuer without regard to your interests and thus may acquire non-public information about the underlying equity. Neither we nor any of our affiliates undertakes to disclose any such information to you. In addition, we or our affiliates from time to time have published and in the future may publish research reports with respect to the underlying equity, which may or may not recommend that investors buy or hold the underlying equity.

￭**Potential UBS impact on an underlying equity.** Trading or transactions by UBS or its affiliates in the underlying equity, listed and/or over the counter options, futures, exchange-traded funds or other instruments with return linked to the performance of the underlying equity, may adversely affect the market price(s) or level(s) of that underlying equity on any determination date or on the final determination date and, therefore, the market value of the securities and any payout to you of any contingent payments or at maturity.

June 2025 Page 11

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

￭**Following certain events, the calculation agent can make adjustments to the underlying equity and terms of the securities that may adversely affect the market value of, and return on, the securities.** The calculation agent may make adjustments to the initial price, trigger price and/or final price or any other term of the securities and, in some instances, may replace the underlying equity, for certain events affecting the underlying equity. However, the calculation agent will not make an adjustment in response to all events that could affect the underlying equity. If an event occurs that does not require the calculation agent to make an adjustment, the value of, and any amounts payable on, the securities may be materially and adversely affected. You should also be aware that the calculation agent may make adjustments in response to events that are not described in the accompanying product supplement that it believes are appropriate to offset to the extent practical any change in your economic position as a holder of the securities resulting solely from any such event to achieve an equitable result, but the calculation agent is under no obligation to do so or to consider your interests as a holder of the securities in making these determinations. Following certain events relating to the underlying equity issuer, such as a reorganization event or a delisting or suspension of trading, the return on the securities may be based on the shares of a successor to the underlying equity issuer in combination with any cash or any other assets distributed to holders of the underlying equity, if applicable, or on the common stock issued by another company. For more information, see the sections "General Terms of the Securities — Antidilution Adjustments for Securities Linked to an Underlying Equity or Equity Basket Asset", "— Reorganization Events for Securities Linked to an Underlying Equity or Equity Basket Asset" and "— Delisting of, Suspension of Trading in, or Change in Law Affecting, an Underlying Equity" in the accompanying product supplement.

***Risks Relating to General Credit Characteristics***

￭**The** **securities are subject to the credit risk of UBS, and any actual or anticipated changes to our credit ratings or credit spreads may adversely affect the market value of the securities.** Investors are dependent on UBS' ability to pay all amounts due on the securities, and therefore investors are subject to our credit risk and to changes in the market's view of our creditworthiness. Any actual or anticipated decline in our credit ratings or increase in the credit spreads charged by the market for taking our credit risk is likely to affect adversely the market value of the securities. If we were to default on our payment obligations, you may not receive any amounts owed to you under the securities and you could lose a significant portion or all of your initial investment.

￭**The securities are not bank deposits.** An investment in the securities carries risks which are very different from the risk profile of a bank deposit placed with UBS or its affiliates. The securities have different yield and/or return, liquidity and risk profiles and would not benefit from any protection provided to deposits.

￭**If UBS experiences financial difficulties, FINMA has the power to open restructuring or liquidation proceedings in respect of, and/or impose protective measures in relation to, UBS, which proceedings or measures may have a material adverse effect on the terms and market value of the securities and/or the ability of UBS to make payments thereunder.** The Swiss Federal Act on Banks and Savings Banks of November 8, 1934, as amended (the "Swiss Banking Act") grants the Swiss Financial Market Supervisory Authority ("FINMA") broad powers to take measures and actions in relation to UBS if it concludes that there is justified concern that UBS is over-indebted or has serious liquidity problems or, after expiry of a deadline, UBS fails to fulfill the applicable capital adequacy requirements (whether on a standalone or consolidated basis). If one of these pre-requisites is met, FINMA is authorized to open restructuring proceedings or liquidation (bankruptcy) proceedings in respect of, and/or impose protective measures in relation to, UBS. The Swiss Banking Act grants significant discretion to FINMA in connection with the aforementioned proceedings and measures. In particular, a broad variety of protective measures may be imposed by FINMA, including a bank moratorium or a maturity postponement, which measures may be ordered by FINMA either on a stand-alone basis or in connection with restructuring or liquidation proceedings.

June 2025 Page 12

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

In restructuring proceedings, FINMA, as resolution authority, is competent to approve the restructuring plan. The restructuring plan may, among other things, provide for (a) the transfer of all or a portion of UBS' assets, debts, other liabilities and contracts (which may or may not include the contractual relationship between UBS and the holders of securities) to another entity, (b) a stay (for a maximum of two business days) on the termination of contracts to which UBS is a party, and/or the exercise of (w) rights to terminate, (x) netting rights, (y) rights to enforce or dispose of collateral or (z) rights to transfer claims, liabilities or collateral under contracts to which UBS is a party, (c) the partial or full conversion of UBS' debt and/or other obligations, including its obligations under the securities, into equity (a "debt-to-equity swap"), and/or (d) the partial or full write-off of obligations owed by UBS (a "write-off"), including its obligations under the securities. Prior to any debt-to-equity swap or write-off with respect to any securities, outstanding equity and debt instruments issued by UBS qualifying as additional tier 1 capital or tier 2 capital must be converted or written-down, as applicable, and cancelled. The Swiss Banking Act addresses the order in which a debt-to-equity swap or a write-off of debt instruments (other than debt instruments qualifying as additional tier 1 capital or tier 2 capital) should occur: first, all subordinated obligations not qualifying as regulatory capital; second, debt instruments for loss absorbency in the course of insolvency measures (*Schuldinstrumente zur Verlusttragung im Falle von Insolvenzmassnahmen*) under the Swiss Ordinance concerning Capital Adequacy and Risk Diversification for Banks and Securities Dealers of June 1, 2012, as amended; third, all other obligations not excluded by law from a debt-to-equity swap or write-off (other than deposits), such as the securities; and fourth, deposits to the extent in excess of the amount privileged by law. However, given the broad discretion granted to FINMA, any restructuring plan approved by FINMA in connection with restructuring proceedings with respect to UBS could provide that the claims under or in connection with the securities will be fully or partially converted into equity or written-off, while preserving other obligations of UBS that rank *pari passu* with UBS' obligations under the securities. Consequently, the exercise by FINMA of any of its statutory resolution powers or any suggestion of any such exercise could materially adversely affect the rights of holders of the securities, the price or value of their investment in the securities and/or the ability of UBS to satisfy its obligations under the securities and could lead to holders losing some or all of their investment in the securities.

Once FINMA has opened restructuring proceedings with respect to UBS, it may consider factors such as the results of operations, financial condition (in particular, the level of indebtedness, potential future losses and/or restructuring costs), liquidity profile and regulatory capital adequacy of UBS and its subsidiaries, or any other factors of its choosing, when determining whether to exercise any of its statutory resolution powers with respect to UBS, including, if it chooses to exercise such powers to order a debt-to- equity swap and/or a write-off, whether to do so in full or in part. The criteria that FINMA may consider in exercising any statutory resolution power provide it with considerable discretion. Therefore, holders of the securities may not be able to refer to publicly available criteria in order to anticipate a potential exercise of any such power and, consequently, its potential effects on the securities and/or UBS.

If UBS were to be subject to restructuring proceedings, the creditors whose claims are affected by the restructuring plan would not have a right to vote on, reject, or seek the suspension of the restructuring plan. In addition, if a restructuring plan with respect to UBS has been approved by FINMA, the rights of a creditor to challenge the restructuring plan or have the restructuring plan reviewed by a judicial or administrative process or otherwise (e.g., on the grounds that the plan would unduly prejudice the rights of holders of securities or otherwise be in violation of the Swiss Banking Act) are very limited. Even if any of UBS' creditors were to successfully challenge the restructuring plan in court, the court could only require the relevant creditors to be compensated ex post and there is currently no guidance as to on what basis such compensation would be calculated and how it would be funded. Any such challenge (even if successful) would not suspend, or result in the suspension of, the implementation of the restructuring plan.

***Risks Relating to U.S. Federal Income Taxation***

￭**Uncertain** **tax treatment.** Significant aspects of the tax treatment of the securities are uncertain. You should consult your tax advisor about your tax situation. See "Tax Considerations" herein and "Material U.S. Federal Income Tax Consequences", including the section "— Securities Treated as Prepaid Derivatives or Prepaid Forwards", in the accompanying product supplement.

June 2025 Page 13

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

Information About the Underlying Equity

**Eli Lilly and Company**

According to publicly available information, Eli Lilly and Company ("Eli Lilly") is a drug manufacturer that discovers, develops, manufactures and markets human pharmaceutical products. Information filed by Eli Lilly with the SEC can be located by reference to its SEC file number: 001-06351, or its CIK Code: 0001783879. Eli Lilly's common stock is listed on the Nasdaq Global Select Market under the ticker symbol "LLY".

**Information as of market close on June 6, 2025:**

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp; **Bloomberg Ticker Symbol:** | &nbsp;&nbsp; LLY UN  | &nbsp;&nbsp; **52 Week High (on August 30, 2024):** | &nbsp;&nbsp; $960.02 |
| &nbsp;&nbsp; **Current Price:** | &nbsp;&nbsp; $769.88 | &nbsp;&nbsp; **52 Week Low (on May 23, 2025):** | &nbsp;&nbsp; $713.71 |
| &nbsp;&nbsp; **52 Weeks Ago (on June 6, 2024):** | &nbsp;&nbsp; $837.29 |  |  |

---

All disclosures contained in this document regarding the underlying equity are derived from publicly available information. UBS has not conducted any independent review or due diligence of any publicly available information with respect to the underlying equity. You should make your own investigation into the underlying equity.

The underlying equity is registered under the Exchange Act. Companies with securities registered under the Exchange Act are required to file financial and other information specified by the SEC periodically. Information filed by the underlying equity issuer with the SEC can be reviewed electronically through a website maintained by the SEC. The address of the SEC's website is http://www.sec.gov. Information filed with the SEC by the underlying equity issuer under the Exchange Act can be located by reference to its SEC file number provided above.

June 2025 Page 14

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

Historical Information

The following table sets forth the published high and low closing prices, as well as the end-of-quarter closing prices, of the underlying equity for the specified period. The closing price of the underlying equity on June 6, 2025 was $769.88 (the "hypothetical initial price"). The graph below sets forth the daily closing prices of the underlying equity for the period from January 1, 2015 through June 6, 2025. The dotted line represents a hypothetical trigger price of $615.90, which is equal to 80.00% of the closing price of the underlying equity on June 6, 2025. We obtained the information in the table below from Bloomberg Professional<sup>®</sup> service ("Bloomberg"), without independent verification. The closing prices may be adjusted by Bloomberg for corporate actions such as stock splits, public offerings, mergers and acquisitions, spin-offs, delistings and bankruptcy. UBS has not undertaken an independent review or due diligence of any publicly available information obtained from Bloomberg. *The historical closing prices of the underlying equity should not be taken as an indication of its future performance, and no assurance can be given as to the closing price of the underlying equity on the valuation date.*

---

| | | | |
|:---|:---|:---|:---|
|  **Eli Lilly and Company**  | **High** | **Low** | **Period End** |
| **2021** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First Quarter | $212.72 | $164.32 | $186.82 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second Quarter | $233.54 | $180.55 | $229.52 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Third Quarter | $272.71 | $221.60 | $231.05 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fourth Quarter | $279.04 | $224.85 | $276.22 |
| **2022** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First Quarter | $291.66 | $234.69 | $286.37 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second Quarter | $327.27 | $278.73 | $324.23 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Third Quarter | $334.38 | $296.48 | $323.35 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fourth Quarter | $374.76 | $321.55 | $365.84 |
| **2023** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First Quarter | $364.99 | $310.63 | $343.42 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second Quarter | $468.98 | $350.74 | $468.98 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Third Quarter | $599.30 | $434.70 | $537.13 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fourth Quarter | $619.13 | $525.19 | $582.92 |
| **2024** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First Quarter | $792.28 | $592.20 | $777.96 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second Quarter | $909.04 | $724.87 | $905.38 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Third Quarter | $960.02 | $772.14 | $885.94 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fourth Quarter | $932.06 | $727.20 | $772.00 |
| **2025** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; First Quarter | $929.72 | $725.72 | $825.91 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Second Quarter (through June 6, 2025) | $898.95 | $713.71 | $769.88 |

---

June 2025 Page 15

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

&nbsp;&nbsp; **The Common Stock of Eli Lilly and Company – Daily Closing Prices**<br> **From January 1, 2015 to June 6, 2025**<br>

![](image_003.jpg)

**This document relates only to the securities offered hereby and does not relate to the underlying equity or other securities linked to the underlying equity. We have derived all disclosures contained in this document regarding the underlying equity from the publicly available documents described in the preceding paragraphs. In connection with the offering of the securities, neither we nor the agent has participated in the preparation of such documents or made any due diligence inquiry with respect to the underlying equity.**

**Neither the issuer nor any of its affiliates makes any representation to you as to the performance of the underlying equity.**

June 2025 Page 16

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

Additional Information About the Securities

Please read the information in conjunction with the summary terms on the front cover of this document.

---

| | |
|:---|:---|
| &nbsp;&nbsp; **Additional Provisions** | &nbsp;&nbsp; **Additional Provisions** |
| &nbsp;&nbsp; **Listing:** | &nbsp;&nbsp;&nbsp; The securities will not be listed or displayed on any securities exchange or any electronic communication network. |
| &nbsp;&nbsp; **Trustee:** | &nbsp;&nbsp;&nbsp; U.S. Bank Trust National Association |
| &nbsp;&nbsp; **Calculation agent:** | &nbsp;&nbsp;&nbsp; UBS Securities LLC |
| &nbsp;&nbsp; **Tax considerations:** | &nbsp;&nbsp;&nbsp; **The U.S. federal income tax consequences of your investment in the securities are uncertain. There are no statutory provisions, regulations, published rulings or judicial decisions addressing the characterization for U.S. federal income tax purposes of securities with terms that are substantially the same as the securities. Some of these tax consequences are summarized below, but we urge you to read the more detailed discussion in "Material U.S. Federal Income Tax Consequences", including the section "— Securities Treated as Prepaid Derivatives or Prepaid Forwards" in the accompanying product supplement and to discuss the tax consequences of your particular situation with your tax advisor. This discussion is based upon the U.S. Internal Revenue Code of 1986, as amended (the "Code"), final, temporary and proposed U.S. Department of the Treasury (the "Treasury") regulations, rulings and decisions, in each case, as available and in effect as of the date hereof, all of which are subject to change, possibly with retroactive effect. Tax consequences under state, local and non-U.S. laws are not addressed herein. No ruling from the U.S. Internal Revenue Service (the "IRS") has been sought as to the U.S. federal income tax consequences of your investment in the securities, and the following discussion is not binding on the IRS.**<br> *U.S. Tax Treatment.* Pursuant to the terms of the securities, UBS and you agree, in the absence of a statutory or regulatory change or an administrative determination or judicial ruling to the contrary, to characterize the securities as prepaid derivative contracts with respect to the underlying equity. If your securities are so treated, you should generally recognize gain or loss upon the taxable disposition of your securities. Such gain or loss should generally be long-term capital gain or loss if you hold your securities for more than one year (otherwise such gain or loss would be short-term capital gain or loss if held for one year or less) in an amount equal to the difference between the amount you receive at such time and the amount you paid for your securities. The deductibility of capital losses is subject to limitations. <br> **Based on certain factual representations received from us, our special U.S. tax counsel, Cadwalader, Wickersham & Taft LLP, is of the opinion that it would be reasonable to treat your securities in the manner described above. However, because there is no authority that specifically addresses the tax treatment of the securities, it is possible that your securities could alternatively be treated for tax purposes as a single contingent payment debt instrument, or pursuant to some other characterization, such that the timing and character of your income from the securities could differ materially and adversely from the treatment described above, as described further under "Material U.S. Federal Income Tax Consequences", including the section "— Securities Treated as Prepaid Derivatives or Prepaid Forwards", in the accompanying product supplement.** <br> *Notice 2008-2*. In 2007, the IRS released a notice that may affect the taxation of holders of the securities. According to Notice 2008-2, the IRS and the Treasury are actively considering whether the holder of an instrument similar to the securities should be required to accrue ordinary income on a current basis. It is not possible to determine what guidance they will ultimately issue, if any. It is possible, however, that under such guidance, holders of the securities will ultimately be required to accrue income currently and this could be applied on a retroactive basis. The IRS and the Treasury are also considering other relevant issues, including whether additional gain or loss from such instruments should be treated as ordinary or capital, whether non-U.S. holders of such instruments should be subject to withholding tax on any deemed income accruals and whether the special "constructive ownership rules" of Section 1260 of the Code should be applied to such instruments. Both U.S. and non-U.S. holders are urged to consult their tax advisors concerning the significance, and the potential impact, of the above considerations.  |

---

June 2025 Page 17

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

&nbsp;&nbsp;&nbsp; *Medicare Tax on Net Investment Income.* U.S. holders that are individuals, estates or certain trusts are subject to an additional 3.8% tax on all or a portion of their "net investment income", which may include any income or gain realized with respect to the securities, to the extent of their net investment income that when added to their other modified adjusted gross income, exceeds $200,000 for an unmarried individual, $250,000 for a married taxpayer filing a joint return (or a surviving spouse), $125,000 for a married individual filing a separate return or the amount at which the highest tax bracket begins for an estate or trust. The 3.8% Medicare tax is determined in a different manner than the income tax. U.S. holders should consult their tax advisors with respect to their consequences with respect to the 3.8% Medicare tax.<br> *Specified Foreign Financial Assets*. Certain U.S. holders that own "specified foreign financial assets" in excess of an applicable threshold may be subject to reporting obligations with respect to such assets with their tax returns, especially if such assets are held outside the custody of a U.S. financial institution. U.S. holders are urged to consult their tax advisors as to the application of this legislation to their ownership of the securities. <br> *Non-U.S. Holders.* Subject to Section 871(m) of the Code and FATCA (as discussed below), if you are not a U.S. holder, you should generally not be subject to U.S. withholding tax with respect to payments on your securities and you should not be subject to generally applicable information reporting and backup withholding requirements with respect to payments on your securities if you comply with certain certification and identification requirements, including providing us (and/or the applicable withholding agent) with a validly executed and fully completed applicable IRS Form W-8. Subject Section 897 of the Code and Section 871(m) of the Code, discussed below, gain realized from the taxable disposition of a securities generally should not be subject to U.S. tax unless (i) such gain is effectively connected with a trade or business conducted by the non-U.S. holder in the U.S., (ii) the non-U.S. holder is a non-resident alien individual and is present in the U.S. for 183 days or more during the taxable year of such taxable disposition and certain other conditions are satisfied or (iii) the non-U.S. holder has certain other present or former connections with the U.S.<br> *Section 897*. We will not attempt to ascertain whether the underlying equity issuer would be treated as a "United States real property holding corporation" ("USRPHC") within the meaning of Section 897 of the Code. We also have not attempted to determine whether the securities should be treated as "United States real property interests" ("USRPI") as defined in Section 897 of the Code. If the underlying equity issuer and the securities were so treated, certain adverse U.S. federal income tax consequences could possibly apply, including subjecting any gain to a non-U.S. holder in respect of a security upon a taxable disposition of the security to the U.S. federal income tax on a net basis, and the proceeds from such a taxable disposition may be subject to a 15% withholding tax. Non-U.S. holders should consult their tax advisors regarding the potential treatment of the underlying equity issuer as a USRPHC and the securities as USRPI.<br> *Section 871(m).* A 30% withholding tax (which may be reduced by an applicable income tax treaty) is imposed under Section 871(m) of the Code on certain "dividend equivalents" paid or deemed paid to a non-U.S. holder with respect to a "specified equity-linked instrument" that references one or more dividend-paying U.S. equity securities. The withholding tax can apply even if the instrument does not provide for payments that reference dividends. Treasury regulations provide that the withholding tax applies to all dividend equivalents paid or deemed paid on specified equity-linked instruments that have a delta of one ("delta one specified equity-linked instruments") issued after 2016 and to all dividend equivalents paid or deemed paid on all other specified equity-linked instruments issued after 2017. However, the IRS has issued guidance that states that the Treasury and the IRS intend to amend the effective dates of the Treasury regulations to provide that withholding on dividend equivalents paid or deemed paid will not apply to specified equity-linked instruments that are not delta-one specified equity-linked instruments and are issued before January 1, 2027.<br> Based on our determination that the securities are not "delta-one" with respect to the underlying equity, our special U.S. tax counsel is of the opinion that the securities should not be delta-one specified equity-linked instruments and thus should not be subject to withholding on dividend equivalents. Our determination is not binding on the IRS, and the IRS may disagree with this determination. Furthermore, the application of Section 871(m) of the Code will depend on our determinations made on the date the terms of the securities are set. If withholding is required, we will not make payments of any additional amounts.<br> Nevertheless, after the date the terms are set, it is possible that your securities could be deemed to be reissued for tax purposes upon the occurrence of certain <br>

June 2025 Page 18

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;&nbsp; events affecting the underlying equity or your securities, and following such occurrence your securities could be treated as delta-one specified equity-linked instruments that are subject to withholding on dividend equivalents. It is also possible that withholding tax or other tax under Section 871(m) of the Code could apply to the securities under these rules if you enter, or have entered, into certain other transactions in respect of the underlying equity or the securities. If you enter, or have entered, into other transactions in respect of the underlying equity or the securities, you should consult your tax advisor regarding the application of Section 871(m) of the Code to your securities in the context of your other transactions.<br> **Because of the uncertainty regarding the application of the 30% withholding tax on dividend equivalents to the securities, you are urged to consult your tax advisor regarding the potential application of Section 871(m) of the Code and the 30% withholding tax to an investment in the securities.**<br> *Foreign Account Tax Compliance Act.* Legislation commonly referred to as the Foreign Account Tax Compliance Act ("FATCA") generally imposes a withholding tax of 30% on payments to certain non-U.S. entities (including financial intermediaries) with respect to certain financial instruments, unless various U.S. information reporting and due diligence requirements have been satisfied. An intergovernmental agreement between the U.S. and the non-U.S. entity's jurisdiction may modify these requirements. This legislation generally applies to certain financial instruments that are treated as paying U.S.-source interest or other U.S.-source "fixed or determinable annual or periodical" income ("FDAP income"). Withholding (if applicable) applies to payments of U.S.-source FDAP income but, pursuant to certain Treasury regulations and IRS guidance, does not apply to payments of gross proceeds on the disposition (including upon retirement) of financial instruments. As the treatment of the securities is unclear, it is possible that any payment with respect to the securities could be subject to the FATCA rules. If withholding applies to the securities, we will not be required to pay any additional amounts with respect to amounts withheld. Both U.S. and non-U.S. holders should consult their tax advisors regarding the potential application of FATCA to the securities.<br> *Proposed Legislation.* In 2007, legislation was introduced in Congress that, if it had been enacted, would have required holders of securities similar to the securities purchased after the bill was enacted to accrue interest income over the term of such securities despite the fact that there will be no interest payments over the term of such securities.<br> Furthermore, in 2013, the House Ways and Means Committee released in draft form certain proposed legislation relating to financial instruments. If it had been enacted, the effect of this legislation generally would have been to require instruments such as the securities to be marked to market on an annual basis with all gains and losses to be treated as ordinary, subject to certain exceptions.<br> It is not possible to predict whether any similar or identical bills will be enacted in the future, or whether any such bill would affect the tax treatment of your securities. You are urged to consult your tax advisor regarding the possible changes in law and their possible impact on the tax treatment of your securities.<br> **Both U.S. and non-U.S. holders are urged to consult their tax advisors concerning the application of U.S. federal income tax laws to their particular situations, as well as any tax consequences of the purchase, beneficial ownership and disposition of the securities arising under the laws of any state, local, non-U.S. or other taxing jurisdiction.** |
| &nbsp;&nbsp; **Use of proceeds and hedging:** | &nbsp;&nbsp;&nbsp; We will use the net proceeds we receive from the sale of the securities for the purposes we describe in the accompanying prospectus under "Use of Proceeds and Hedging." We and/or our affiliates may also use those proceeds in transactions intended to hedge our obligations under the securities as described below.  |
|  | &nbsp;&nbsp;&nbsp; In connection with the sale of the securities, we and/or our affiliates may enter into hedging transactions involving the execution of long-term or short-term interest rate swaps, futures and option transactions or purchases and sales of securities before, on and after the pricing date of the securities. From time to time, we and/or our affiliates may enter into additional hedging transactions or unwind those we have entered into. In addition, we or one of our affiliates may enter into swap agreements or related hedging activities with the dealer or its affiliates.<br> We and/or our affiliates may acquire a long or short position in securities similar to the securities from time to time and may, in our or their sole discretion, hold or resell those securities.<br> The hedging activity discussed above may adversely affect the market value of the securities from time to time and payment on the securities at maturity. See "Risk Factors" herein for a discussion of these adverse effects. |

---

June 2025 Page 19

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; **Supplemental** **plan of distribution (conflicts of interest); secondary markets (if any):** | &nbsp;&nbsp;&nbsp; Pursuant to the terms of a distribution agreement, UBS will agree to sell to UBS Securities LLC, and UBS Securities LLC will agree to purchase from UBS, the stated principal amount of the securities specified on the front cover of this document at the price to public less a fee of $25.00 per security. UBS Securities LLC will agree to resell all of the securities to Morgan Stanley Wealth Management with an underwriting discount of $25.00 reflecting a fixed sales commission of $20.00 and a fixed structuring fee of $5.00 per $1,000.00 stated principal amount of securities that Morgan Stanley Wealth Management sells. UBS or an affiliate will also pay a fee to LFT Securities, LLC, an entity in which an affiliate of Morgan Stanley Wealth Management and an affiliate of UBS Securities LLC each has an ownership interest, for providing certain electronic platform services with respect to this offering. <br> UBS, UBS Securities LLC or any other affiliate of UBS may use this document, the accompanying product supplement and the accompanying prospectus in a market-making transaction for any securities after their initial sale. In connection with the offering, UBS, UBS Securities LLC, any other affiliate of UBS or any other securities dealers may distribute this document, the accompanying product supplement, the and the accompanying prospectus electronically. Unless UBS or its agent informs the purchaser otherwise in the confirmation of sale, this document, the accompanying product supplement and the accompanying prospectus are being used in a market-making transaction.<br> **Conflicts of Interest —** UBS Securities LLC is an affiliate of UBS and, as such, has a "conflict of interest" in this offering within the meaning of Financial Industry Regulatory Authority, Inc. ("FINRA") Rule 5121. In addition, UBS will receive the net proceeds from the initial public offering of the securities, thus creating an additional conflict of interest within the meaning of FINRA Rule 5121. UBS Securities LLC is not permitted to sell the securities in this offering to an account over which it exercises discretionary authority without the prior specific written approval of the account holder.<br> **UBS Securities LLC and its affiliates may offer to buy or sell the securities in the secondary market (if any) at prices greater than UBS' internal valuation** — The value of the securities at any time will vary based on many factors that cannot be predicted. However, the price (not including UBS Securities LLC's or any affiliate's customary bid-ask spreads) at which UBS Securities LLC or any affiliate would offer to buy or sell the securities immediately after the pricing date in the secondary market is expected to exceed the estimated initial value of the securities as determined by reference to our internal pricing models. The amount of the excess will decline to zero on a straight line basis over a period ending no later than 6 weeks after the pricing date, provided that UBS Securities LLC may shorten the period based on various factors, including the magnitude of purchases and other negotiated provisions with selling agents. Notwithstanding the foregoing, UBS Securities LLC and its affiliates are not required to make a market for the securities and may stop making a market at any time. For more information about secondary market offers and the estimated initial value of the securities, see "Risk Factors — Estimated Value Considerations" and "— Risks Relating to Liquidity and Secondary Market Price Considerations" in this document. |
| &nbsp;&nbsp;&nbsp; **Prohibition of sales to EEA retail investors** **:**  | &nbsp;&nbsp;&nbsp; The securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (the "EEA"). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, "MiFID II"); or (ii) a customer within the meaning of Directive (EU) 2016/97, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Regulation (EU) 2017/1129, as amended. Consequently no key information document required by Regulation (EU) No 1286/2014 (the "EU PRIIPs Regulation") for offering or selling the securities or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the securities or otherwise making them available to any retail investor in the EEA may be unlawful under the EU PRIIPs Regulation. |

---

June 2025 Page 20

------

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](image2.jpg) <br>|
| Trigger Jump Securities due on or about December 24, 2026<br> $**●** Based on the Performance of the common stock of Eli Lilly and Company<br> Principal at Risk Securities |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; **Prohibition** **on sales to UK retail investors:** | &nbsp;&nbsp;&nbsp; The securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the United Kingdom ("UK"). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client, as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the "EUWA"); (ii) a customer within the meaning of the provisions of the Financial Services and Markets Act 2000 (the "FSMA") and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97, where that customer would not qualify as a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA. Consequently no key information document required by Regulation (EU) No 1286/2014 as it forms part of domestic law by virtue of the EUWA (the "UK PRIIPs Regulation") for offering or selling the securities or otherwise making them available to retail investors in the UK has been prepared and therefore offering or selling the securities or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation. |
| &nbsp;&nbsp; **This document represents a summary of the terms and conditions of the securities. We encourage you to read the accompanying product supplement and accompanying prospectus related to this offering, which can be accessed via the hyperlinks on page 2 of this document.** | &nbsp;&nbsp; **This document represents a summary of the terms and conditions of the securities. We encourage you to read the accompanying product supplement and accompanying prospectus related to this offering, which can be accessed via the hyperlinks on page 2 of this document.** |

---

June 2025 Page 21

------

**You should rely only on the information incorporated by reference or provided in this preliminary pricing supplement, the accompanying product supplement or the accompanying prospectus. We have not authorized anyone to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this preliminary pricing supplement is accurate as of any date other than the date on the front of the document.**

**TABLE OF CONTENTS**

**Preliminary Pricing Supplement**

---

| | |
|:---|:---|
| &nbsp;&nbsp; Summary Terms | &nbsp;&nbsp; 1 |
| &nbsp;&nbsp; Additional Information About UBS and the Securities | &nbsp;&nbsp; 2 |
| &nbsp;&nbsp; Investment Overview | &nbsp;&nbsp; 3 |
| &nbsp;&nbsp; Key Investment Rationale | &nbsp;&nbsp; 3 |
| &nbsp;&nbsp; Investor Suitability | &nbsp;&nbsp; 4 |
| &nbsp;&nbsp; How the Securities Work | &nbsp;&nbsp; 5 |
| &nbsp;&nbsp; How it works | &nbsp;&nbsp; 7 |
| &nbsp;&nbsp; Payment at Maturity | &nbsp;&nbsp; 8 |
| &nbsp;&nbsp; Risk Factors | &nbsp;&nbsp; 9 |
| &nbsp;&nbsp; Information About the Underlying Equity | &nbsp;&nbsp; 14 |
| &nbsp;&nbsp; Historical Information | &nbsp;&nbsp; 15 |
| &nbsp;&nbsp; Additional Information About the Securities | &nbsp;&nbsp; 17 |

---

---

| | |
|:---|:---|
|  **Product Supplement** |  |
|  Product Supplement Summary | PS-1 |
|  Specific Terms of Each Security Will Be Described in the Applicable Supplements | PS-1 |
|  The Securities are Part of a Series | PS-1 |
|  Denomination | PS-2 |
|  Coupons | PS-2 |
|  Early Redemption | PS-3 |
|  Payment at Maturity for the Securities | PS-3 |
|  Defined Terms Relating to Payment on the Securities | PS-4 |
|  Valuation Dates | PS-5 |
|  Valuation Periods | PS-6 |
|  Payment Dates | PS-6 |
|  Closing Level | PS-7 |
|  Intraday Level | PS-7 |
|  What are the Tax Consequences of the Securities? | PS-8 |
|  Risk Factors | PS-9 |
|  General Terms of the Securities | PS-26 |
|  Use of Proceeds and Hedging | PS-53 |
|  Material U.S. Federal Income Tax Consequences | PS-54 |
|  Certain ERISA Considerations | PS-77 |
|  Supplemental Plan of Distribution (Conflicts of Interest) | PS-79 |
|  Introduction | 1 |
|  Cautionary Note Regarding Forward-Looking Statements | 3 |
|  Incorporation of Information About UBS AG | 6 |
|  Where You Can Find More Information | 7 |
|  Presentation of Financial Information | 8 |
|  Limitations on Enforcement of U.S. Laws Against UBS AG, Its Management and Others | 8 |
|  UBS AG | 8 |
|  Swiss Regulatory Powers | 10 |
|  Use of Proceeds | 11 |
|  Description of Debt Securities We May Offer | 11 |
|  Description of Warrants We May Offer | 48 |
|  Legal Ownership and Book-Entry Issuance | 65 |
|  Considerations Relating to Indexed Securities | 69 |
|  Considerations Relating to Floating Rate Securities | 72 |
|  Considerations Relating to Securities Denominated or Payable in or Linked to a Non-U.S. Dollar Currency | 75 |
|  U.S. Tax Considerations | 77 |
|  Tax Considerations Under the Laws of Switzerland | 88 |
|  Benefit Plan Investor Considerations | 90 |
|  Plan of Distribution | 92 |

---

---

| | |
|:---|:---|
|  Validity of the Securities | 95 |
|  Experts | 95 |

---

**$●**

**UBS AG <br>Trigger Jump Securities due on or about December 24, 2026**

Preliminary Pricing Supplement dated June 9, 2025<br>(To Product Supplement dated February 6, 2025<br>and Prospectus dated February 6, 2025)

**UBS Investment Bank**

**UBS Securities LLC**